Urovant Sciences cashes in $75m in licence...French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences drug vibegron for the treatment of overactive bladder in Europe. more ➔
CureVac NV sues BioNTech for IP infringeme...German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents. more ➔
French Ipsen falls after Epizyme take-over...Shares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m. more ➔
TWB announces winners in industrial biotec...At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000. more ➔
BIONTech breaks ground for manufacturing s...BioNTech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this years end toKigall. more ➔
Cannabis players Canify AS and Bavaria Wee...In an effort to become a major player in Europes growing pharmaceutical-grade cannabis market, Danish Canify AS and Bavaria Weed GmbH merge to form Canify AG. more ➔
Unilever launches $120m venture with Genom...Under the $120m deal, Genomatica and Unilever will scale plant- and waste-based alternative to palm oil and fossil fuels. more ➔
Roche obtains special authorisation for bi...Roche obtained from European Medicine Agency (EMA) a special authorization (conditional approval) for new bispecific antibody Lunsumio for treatment of relapsed or refractory follicular (R/R) lymphoma … more ➔
Andera Partners, Imcheck therapeutics, Kurma, marseille, Pfizer, wellington French ImCheck get´s a USD103m check by P... ImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, … more ➔
$50m for London CHARM Therapeutics for dee... CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology. more ➔
